Melatonin and celecoxib improve the outcomes in hamsters with experimental pancreatic cancer

Francisco J. Padillo, Juan F. Ruiz-Rabelo, Adolfo Cruz, María D. Perea, Inmaculada Tasset, Pedro Montilla, Isaac Túnez, Jordi Muntané

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Pancreatic cancer is a major health problem because of the aggressiveness of the disease and the lack of effective systemic therapies. Melatonin (MEL) has antioxidant activity and prevents experimental genotoxicity. The specific inhibitor of cyclooxygenase-2 (COX-2), celecoxib (CEL), increases the efficacy of chemoradiotherapy in advanced pancreatic cancer. The objective of the study was the comparison and synergic effect of MEL and CEL during either the induction or progression phases of the tumor process, measuring parameters of oxidative stress, number of tumor nodules and survival of animals with pancreatic cancer. Pancreatic cancer was induced by N-nitrosobis (2-oxopropyl)amine) (BOP) in Syrian hamsters. Melatonin and/or CEL were administered during the induction, postinduction as well as during both phases. The presence of tumor nodules were observed macroscopically in pancreatic and splenic areas, and the levels of lipoperoxides (LPO), reduced glutathione (GSH), superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) in pancreatic tissue were measured. The increases in tumor nodules and LPO as well as the reductions in GSH and enzymatic antioxidants in the pancreas induced by BOP were related to a lower survival rate of animals. The administration of MEL exerted a more potent beneficial effect than CEL treatment on the reduction in tumor nodules, oxidative stress and death of experimental BOP-treated animals. The combined treatment only exerted a synergistic beneficial effect when administered during the induction phase. Melatonin by itself had significant beneficial actions in improving the survival of hamsters.

Original languageEnglish (US)
Pages (from-to)264-270
Number of pages7
JournalJournal of Pineal Research
Volume49
Issue number3
DOIs
StatePublished - Oct 2010
Externally publishedYes

Fingerprint

Celecoxib
Melatonin
Pancreatic Neoplasms
Cricetinae
Lipid Peroxides
nitrosobis(2-oxopropyl)amine
Neoplasms
Oxidative Stress
Antioxidants
Cyclooxygenase 2 Inhibitors
Mesocricetus
Chemoradiotherapy
Glutathione Peroxidase
Catalase
Superoxide Dismutase
Glutathione
Pancreas
Therapeutics

Keywords

  • celecoxib
  • melatonin
  • oxidative stress
  • pancreatic cancer

ASJC Scopus subject areas

  • Endocrinology

Cite this

Padillo, F. J., Ruiz-Rabelo, J. F., Cruz, A., Perea, M. D., Tasset, I., Montilla, P., ... Muntané, J. (2010). Melatonin and celecoxib improve the outcomes in hamsters with experimental pancreatic cancer. Journal of Pineal Research, 49(3), 264-270. https://doi.org/10.1111/j.1600-079X.2010.00791.x

Melatonin and celecoxib improve the outcomes in hamsters with experimental pancreatic cancer. / Padillo, Francisco J.; Ruiz-Rabelo, Juan F.; Cruz, Adolfo; Perea, María D.; Tasset, Inmaculada; Montilla, Pedro; Túnez, Isaac; Muntané, Jordi.

In: Journal of Pineal Research, Vol. 49, No. 3, 10.2010, p. 264-270.

Research output: Contribution to journalArticle

Padillo, FJ, Ruiz-Rabelo, JF, Cruz, A, Perea, MD, Tasset, I, Montilla, P, Túnez, I & Muntané, J 2010, 'Melatonin and celecoxib improve the outcomes in hamsters with experimental pancreatic cancer', Journal of Pineal Research, vol. 49, no. 3, pp. 264-270. https://doi.org/10.1111/j.1600-079X.2010.00791.x
Padillo, Francisco J. ; Ruiz-Rabelo, Juan F. ; Cruz, Adolfo ; Perea, María D. ; Tasset, Inmaculada ; Montilla, Pedro ; Túnez, Isaac ; Muntané, Jordi. / Melatonin and celecoxib improve the outcomes in hamsters with experimental pancreatic cancer. In: Journal of Pineal Research. 2010 ; Vol. 49, No. 3. pp. 264-270.
@article{c06f05ce611740d6ae4776cc6a96fa66,
title = "Melatonin and celecoxib improve the outcomes in hamsters with experimental pancreatic cancer",
abstract = "Pancreatic cancer is a major health problem because of the aggressiveness of the disease and the lack of effective systemic therapies. Melatonin (MEL) has antioxidant activity and prevents experimental genotoxicity. The specific inhibitor of cyclooxygenase-2 (COX-2), celecoxib (CEL), increases the efficacy of chemoradiotherapy in advanced pancreatic cancer. The objective of the study was the comparison and synergic effect of MEL and CEL during either the induction or progression phases of the tumor process, measuring parameters of oxidative stress, number of tumor nodules and survival of animals with pancreatic cancer. Pancreatic cancer was induced by N-nitrosobis (2-oxopropyl)amine) (BOP) in Syrian hamsters. Melatonin and/or CEL were administered during the induction, postinduction as well as during both phases. The presence of tumor nodules were observed macroscopically in pancreatic and splenic areas, and the levels of lipoperoxides (LPO), reduced glutathione (GSH), superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) in pancreatic tissue were measured. The increases in tumor nodules and LPO as well as the reductions in GSH and enzymatic antioxidants in the pancreas induced by BOP were related to a lower survival rate of animals. The administration of MEL exerted a more potent beneficial effect than CEL treatment on the reduction in tumor nodules, oxidative stress and death of experimental BOP-treated animals. The combined treatment only exerted a synergistic beneficial effect when administered during the induction phase. Melatonin by itself had significant beneficial actions in improving the survival of hamsters.",
keywords = "celecoxib, melatonin, oxidative stress, pancreatic cancer",
author = "Padillo, {Francisco J.} and Ruiz-Rabelo, {Juan F.} and Adolfo Cruz and Perea, {Mar{\'i}a D.} and Inmaculada Tasset and Pedro Montilla and Isaac T{\'u}nez and Jordi Muntan{\'e}",
year = "2010",
month = "10",
doi = "10.1111/j.1600-079X.2010.00791.x",
language = "English (US)",
volume = "49",
pages = "264--270",
journal = "Journal of Pineal Research",
issn = "0742-3098",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Melatonin and celecoxib improve the outcomes in hamsters with experimental pancreatic cancer

AU - Padillo, Francisco J.

AU - Ruiz-Rabelo, Juan F.

AU - Cruz, Adolfo

AU - Perea, María D.

AU - Tasset, Inmaculada

AU - Montilla, Pedro

AU - Túnez, Isaac

AU - Muntané, Jordi

PY - 2010/10

Y1 - 2010/10

N2 - Pancreatic cancer is a major health problem because of the aggressiveness of the disease and the lack of effective systemic therapies. Melatonin (MEL) has antioxidant activity and prevents experimental genotoxicity. The specific inhibitor of cyclooxygenase-2 (COX-2), celecoxib (CEL), increases the efficacy of chemoradiotherapy in advanced pancreatic cancer. The objective of the study was the comparison and synergic effect of MEL and CEL during either the induction or progression phases of the tumor process, measuring parameters of oxidative stress, number of tumor nodules and survival of animals with pancreatic cancer. Pancreatic cancer was induced by N-nitrosobis (2-oxopropyl)amine) (BOP) in Syrian hamsters. Melatonin and/or CEL were administered during the induction, postinduction as well as during both phases. The presence of tumor nodules were observed macroscopically in pancreatic and splenic areas, and the levels of lipoperoxides (LPO), reduced glutathione (GSH), superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) in pancreatic tissue were measured. The increases in tumor nodules and LPO as well as the reductions in GSH and enzymatic antioxidants in the pancreas induced by BOP were related to a lower survival rate of animals. The administration of MEL exerted a more potent beneficial effect than CEL treatment on the reduction in tumor nodules, oxidative stress and death of experimental BOP-treated animals. The combined treatment only exerted a synergistic beneficial effect when administered during the induction phase. Melatonin by itself had significant beneficial actions in improving the survival of hamsters.

AB - Pancreatic cancer is a major health problem because of the aggressiveness of the disease and the lack of effective systemic therapies. Melatonin (MEL) has antioxidant activity and prevents experimental genotoxicity. The specific inhibitor of cyclooxygenase-2 (COX-2), celecoxib (CEL), increases the efficacy of chemoradiotherapy in advanced pancreatic cancer. The objective of the study was the comparison and synergic effect of MEL and CEL during either the induction or progression phases of the tumor process, measuring parameters of oxidative stress, number of tumor nodules and survival of animals with pancreatic cancer. Pancreatic cancer was induced by N-nitrosobis (2-oxopropyl)amine) (BOP) in Syrian hamsters. Melatonin and/or CEL were administered during the induction, postinduction as well as during both phases. The presence of tumor nodules were observed macroscopically in pancreatic and splenic areas, and the levels of lipoperoxides (LPO), reduced glutathione (GSH), superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px) in pancreatic tissue were measured. The increases in tumor nodules and LPO as well as the reductions in GSH and enzymatic antioxidants in the pancreas induced by BOP were related to a lower survival rate of animals. The administration of MEL exerted a more potent beneficial effect than CEL treatment on the reduction in tumor nodules, oxidative stress and death of experimental BOP-treated animals. The combined treatment only exerted a synergistic beneficial effect when administered during the induction phase. Melatonin by itself had significant beneficial actions in improving the survival of hamsters.

KW - celecoxib

KW - melatonin

KW - oxidative stress

KW - pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=77956330076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956330076&partnerID=8YFLogxK

U2 - 10.1111/j.1600-079X.2010.00791.x

DO - 10.1111/j.1600-079X.2010.00791.x

M3 - Article

VL - 49

SP - 264

EP - 270

JO - Journal of Pineal Research

JF - Journal of Pineal Research

SN - 0742-3098

IS - 3

ER -